Related Experiment Videos

The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance

M Kavallaris1

  • 1Children's Cancer Research Institute, Sydney Children's Hospital, Randwick, NSW, Australia.

Anti-Cancer Drugs
|January 1, 1997
PubMed

Insights

Multidrug resistance (MDR) poses a significant challenge in cancer treatment. This review details the multidrug resistance-associated protein (MRP), a key factor in chemotherapy resistance, and its role in drug-refractory cancers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Multidrug resistance (MDR) is a major obstacle in treating neoplastic diseases.
  • MDR involves resistance to multiple chemotherapeutic drugs, observed in cell lines and human cancers.
  • Two primary mechanisms for MDR involve efflux pumps: P-glycoprotein (MDR1 gene product) and multidrug resistance-associated protein (MRP).

Purpose of the Study:

  • To provide an overview of the multidrug resistance-associated protein (MRP).
  • To describe the phenotypic and genotypic characteristics of MRP.
  • To discuss the potential relevance of MRP in drug-refractory cancers.

Main Methods:

  • Literature review of existing studies on multidrug resistance mechanisms.
  • Analysis of phenotypic characteristics associated with MRP.
  • Examination of genotypic data related to MRP expression.

Main Results:

  • MRP, like P-glycoprotein, belongs to the ATP-binding cassette superfamily of transporters.
  • Despite low homology with P-glycoprotein, MRP mediates resistance to a similar range of chemotherapeutic drugs.
  • Less is known about MRP compared to P-glycoprotein, highlighting a gap in current understanding.

Conclusions:

  • MRP is a significant factor in multidrug resistance in cancer.
  • Understanding MRP's characteristics is crucial for addressing drug-refractory cancers.
  • Further research into MRP may reveal new therapeutic strategies for overcoming chemotherapy resistance.

Related Concept Videos